Literature DB >> 25164199

Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.

Hanjing Emily Wu1, Olaoluwa O Okusaga.   

Abstract

Antipsychotic medication-induced dysphoria is a relatively under-recognized and understudied effect of antipsychotic medication. Although the term is encountered in clinical practice and in the literature, there is no consensus regarding its exact meaning. This article is a narrative review of the literature on antipsychotic medication and dysphoria based on a pubmed database search. We found that antipsychotic medication-induced dysphoria is a term used to describe a negative and unpleasant affective state which seems to be more often associated with high potency first-generation antipsychotics and could potentially lead to medication non-adherence. Though it is plausible to expect antipsychotic medication-induced dysphoria to be related to extrapyramidal symptoms, most especially akathisia, the nature of the association remains unspecified. Furthermore, there is some evidence that dopamine blockade maybe involved in the pathogenesis of antipsychotic medication-induced dysphoria. However, the limited methods of the currently available studies make it impossible to conclusively address the question of which class of antipsychotic (first- or second-generation) has a higher prevalence and severity of the syndrome.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25164199     DOI: 10.1007/s11126-014-9319-1

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  37 in total

1.  Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting.

Authors:  Peter E Cook; Joel O Goldberg; Ryan J Van Lieshout
Journal:  Can J Psychiatry       Date:  2002-11       Impact factor: 4.356

2.  Antipsychotic drug-induced dysphoria.

Authors:  G Lynch; J F Green; D J King
Journal:  Br J Psychiatry       Date:  1996-10       Impact factor: 9.319

3.  Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse.

Authors:  L N Voruganti; R J Heslegrave; A G Awad
Journal:  J Nerv Ment Dis       Date:  1997-07       Impact factor: 2.254

Review 4.  Molecular mechanisms of drug reinforcement and addiction.

Authors:  D W Self; E J Nestler
Journal:  Annu Rev Neurosci       Date:  1995       Impact factor: 12.449

Review 5.  Neurobiology of depression: focus on dopamine.

Authors:  H C Fibiger
Journal:  Adv Biochem Psychopharmacol       Date:  1995

6.  Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

Authors:  L Voruganti; L Cortese; L Oyewumi; Z Cernovsky; S Zirul; A Awad
Journal:  Schizophr Res       Date:  2000-06-16       Impact factor: 4.939

7.  Subjective response to antipsychotic drugs.

Authors:  T Van Putten; P R May; S R Marder; L A Wittmann
Journal:  Arch Gen Psychiatry       Date:  1981-02

Review 8.  What's in a name? The evolution of the nomenclature of antipsychotic drugs.

Authors:  Caroline King; Lakshmi N P Voruganti
Journal:  J Psychiatry Neurosci       Date:  2002-05       Impact factor: 6.186

Review 9.  Neuroleptic dysphoria: towards a new synthesis.

Authors:  L Voruganti; A G Awad
Journal:  Psychopharmacology (Berl)       Date:  2003-11-27       Impact factor: 4.530

10.  Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas Faries; Ron Landbloom; Marvin Swartz; Jeff Swanson
Journal:  BMC Psychiatry       Date:  2006-02-21       Impact factor: 3.630

View more
  3 in total

1.  Specificity of the Relationships Between Dysphoria and Related Constructs in an Outpatient Sample.

Authors:  Vladan Starcevic; David Berle; Kirupamani Viswasam; Anthony Hannan; Denise Milicevic; Vlasios Brakoulias; Erin Dale
Journal:  Psychiatr Q       Date:  2015-12

2.  Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services.

Authors:  Carol Paton; Tom K J Craig; Brittany McConnell; Thomas R E Barnes
Journal:  Ther Adv Psychopharmacol       Date:  2021-04-08

3.  The Effects of Bi-Anodal tDCS Over the Prefrontal Cortex Regions With Extracephalic Reference Placement on Insight Levels and Cardio-Respiratory and Autonomic Functions in Schizophrenia Patients and Exploratory Biomarker Analyses for Treatment Response.

Authors:  Chuan-Chia Chang; Yu-Chen Kao; Che-Yi Chao; Nian-Sheng Tzeng; Hsin-An Chang
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.